Neumora Therapeutics, Inc. (NMRA) — Cash Flow-to-Debt Ratio
Neumora Therapeutics, Inc. (NMRA) has a Cash Flow-to-Debt Ratio of -1.02x as of September 2025, meaning its operating cash flow of $-46.63 Million could theoretically repay -1% of its total liabilities ($45.67 Million) in one year. Explore NMRA long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Neumora Therapeutics, Inc. Cash Flow-to-Debt Ratio (2019–2024)
Historical debt coverage capacity for Neumora Therapeutics, Inc. across 6 annual periods. Also explore NMRA current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Neumora Therapeutics, Inc. (2019–2024)
Year-by-year debt coverage analysis for Neumora Therapeutics, Inc.. For market capitalisation and broader financial context, see market cap of Neumora Therapeutics, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -6.12x | $-182.94 Million | $29.91 Million | ▼ -1.6% |
| 2023 | -6.02x | $-163.28 Million | $27.12 Million | ▼ -4475.1% |
| 2022 | -0.13x | $-114.90 Million | $873.08 Million | ▼ -31.7% |
| 2021 | -0.10x | $-75.42 Million | $754.52 Million | ▼ -9.2% |
| 2020 | -0.09x | $-26.76 Million | $292.33 Million | ▲ +100.0% |
| 2019 | -1274.29x | $-26.76 Million | $21.00K | — |